Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (3323)	6/22/1998 4:09:00 PM
From: Nick	Read Replies (1) \| Respond to of 5736

Hmm, Is that why you got scared?

To: Mama Bear who wrote (3323)	6/22/1998 4:14:00 PM
From: BuzzVA	Respond to of 5736

Stock was nice and weak on the news. The market saw right through the smoke and mirrors. Barbarian, You know as well as I that there's nothing gonna move this stock significantly until the deal(s) is/are announced and there are some hard numbers to crunch. Until then, you can run and play on the grave of CCSI stock all you want. Consider it getting its beauty sleep. ;~) I used to think you knew what you were talking about (quite a while ago). Now you're just as transparent as the so-called CCSI releases you mock. All my love, Buzz

To: Mama Bear who wrote (3323)	6/22/1998 5:30:00 PM
From: Steve	Read Replies (2) \| Respond to of 5736

Here is the problem with CCSI's bilirubin screening test: Jaundice occurs in 50% of all newborns and reflects an accumulation of bilirubin in the blood and other tissues. In most cases this resolves within a couple days without any treatment. Bilirubin exists in two forms, CONJUGATED and UNCONJUGATED. The TLc-BiliTest from Chromatics only measures the total bilirubin (conjugated + unconjugated = total bilirubin). The initial evaluation of an infant that is jaundice is to measure the conjugated and unconjugated concentrations of bilirubin. This can only be done with a blood test. You have to know both levels of bilirubin because depending on which one (conjugated or unconjugated) is elevated that determines your next step in the work-up of the patient. The point is that a doctor already knows the baby is jaundice just by looking at him, he does not need a device to tell him that. The doctor's next question he needs answered is which type of bilirubin is elevated, conjugated or unconjugated. Knowing the total bilirubin, which is what the TLc-BiliTest does, is useless. The doctor must order a blood test. This is why CCSI has not been able to sell one single device to a hospital in the U.S. in the past year. I'm sure the TLc-BiliTest works but the information it gives the doctor is essentially useless. Once a doctor got the reading from the TLc-BiliTest he would then have to do a blood test.

To: Mama Bear who wrote (3323)	6/22/1998 5:55:00 PM
From: Robin	Read Replies (1) \| Respond to of 5736

Barb, Can you believe the tenacity of these longs? Recklessly disregarding the fact that this stock may not be worth buying even at this price. CCSI labels the news release as a major milestone. What a laugh! An agreement to launch a study that may determine what, if any, the appropriate usage and price for this product would be in the People's Republic of China. And we all get to wait three months to find out the results of this study and what, if any, revenues are suggested that will come out of this market. After three months, we'll probably get another study (i.e., more bribe money necessary). The only major milestone I see is that this release will be instrumental in dragging out the inevitable collapse of this company several weeks longer as more uninformed money trickles in! Now, to get to the real numbers we can hope to get from the study. What realistically does anyone think the average parent in China can afford? Half of the population is rural and will not be able to afford this or any other test at any price! Next, half of the births are female and the survival of such infants are of little concern to many (my apologies to those of you offended by this, but it is a reality that female infanticide is prevalent in China). After this, does anyone have a realistic figure as to how many births in China occur in hospitals? In the cities (Hong Kong, Beijing, And Shanghai), the Bili-Chek might be used but only if it is available and only if it costs less than the heel prick. Does anyone out there know what is charged for the heel prick test in your average Chinese hospital? or do they even perform this test! I think once one makes a legitimate attempt to calculate the revenue stream from this market, even the most optimistic calculations will be marginal. And don't forget the necessary bribes which need to be made continually to the appropriate Chinese officials (apparently being made now or else we would not have had this news release). Wall Street knows this and showed it in the lack of effect this announcement had on the price today. With the advent of this announcement, I would be led to believe that CCSI has been unable to complete a manufacturing and distribution agreement with any major medical manufacturer in the US or Europe. To put emphasis (read: major milestone) on this deal (with China) and the insignificant immediate financial impact it offers, it just lends greater credibility to the belief that CCSI management is bluffing. It looks like Darby is making one last ditch effort to get a manufacturing partnership going and this may be the last meager opportunity left to her. So there it is, as Gipper (post 3161) and CCSI (I believe he was quoting Jennifer) had promised two Friday's ago, we would not see the deal last week, or over this past weekend, but rather this week. 'THE DEAL' has been made. Well, we now have 'THE DEAL', and guess who's been dealt! Unfortunately chuckling at those still in denial and long! Rockin' Robin